No Data
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) 36% Price Boost Is Out Of Tune With Earnings
Shanghai Haoyuan Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Haoyuan Pharmaceutical (688131.SH): the net income in the first three quarters was 0.143 billion yuan, with a year-on-year growth of 21.31%.
On October 29th, Haoyuan Medicine (688131.SH) announced that in the first three quarters of 2024, it achieved total operating income of 1.619 billion yuan, an increase of 17.65% year-on-year; the net income attributable to the parent company's shareholders was 0.143 billion yuan, a year-on-year increase of 21.31%; and the basic earnings per share was 0.68 yuan.
October 29th A-share investment lightning rod │ West Point Pharmaceutical: Shareholders Guotou High-Tech and Hangzhou Chuanghe plan to collectively reduce their shareholding by no more than 3%.
Observing Defense: Stocks may be subject to other risk warnings.
Haoyuan Pharmaceutical (688131.SH) plans to distribute 0.04 yuan per share in dividends on October 25th.
Haoyuan Pharmaceutical (688131.SH) announced that the company's interim dividend distribution plan for the first half of 2024 is: a cash dividend of 0 per share...
Shanghai Haoyuan Chemexpress (SHSE:688131) Takes On Some Risk With Its Use Of Debt
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) P/E Is Still On The Mark Following 31% Share Price BounceNo Data
No Data
